Poly (ADP-ribose) polymerase (PARP) inhibitor regimens ...
Network meta-analysis of PARP inhibitor regimens in BRCA-mutated ovarian cancer showed no significant differences in efficacy and toxicity between upfront and relapsed settings. ASCO value framework indicated similar clinical benefits and net health benefit, with upfront regimens having lower toxicity. Adding bevacizumab to olaparib increased cost per unit net health benefit.
Reference News
Network meta-analysis of PARP inhibitor regimens in BRCA-mutated ovarian cancer showed no significant differences in efficacy and toxicity between upfront and relapsed settings. ASCO value framework indicated similar clinical benefits and net health benefit, with upfront regimens having lower toxicity. Adding bevacizumab to olaparib increased cost per unit net health benefit.